✦ LIBER ✦

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

✍ Scribed by R. E. Pratley; M. S. Kipnes; P. R. Fleck; C. Wilson; Q. Mekki; Alogliptin Study 007 Group

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of the dipeptidyl pe

✍ I. Raz; M. Hanefeld; L. Xu; C. Caria; D. Williams-Herman; H. Khatami; Sitaglipti 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 160 KB

Efficacy and safety of the dipeptidyl pe

✍ K. Hermansen; M. Kipnes; E. Luo; D. Fanurik; H. Khatami; P. Stein; Sitagliptin S 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB

Long-term safety, tolerability, and effi

✍ Masato Odawara; Takashi Kadowaki; Naoko Tajima; Mikio Nishii; Tadaaki Taniguchi; 📂 Article 📅 2011 🏛 Springer Japan 🌐 English ⚖ 377 KB

Efficacy and safety of the dipeptidyl pe

✍ M. A. Nauck; G. Meininger; D. Sheng; L. Terranella; P. P. Stein; Sitagliptin Stu 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB

Fifty-two-week efficacy and safety of vi

✍ E. Ferrannini; V. Fonseca; B. Zinman; D. Matthews; B. Ahrén; S. Byiers; Q. Shao; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 408 KB

The dipeptidyl peptidase-4 inhibitor PHX

✍ G. Garcia-Soria; G. Gonzalez-Galvez; G. M. Argoud; M. Gerstman; T. W. Littlejohn 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB